You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Medtronic
McKesson
Boehringer Ingelheim
McKinsey
AstraZeneca
Harvard Business School

Last Updated: February 29, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 207202


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

NDA 207202 describes ABILIFY MYCITE KIT, which is a drug marketed by Otsuka Pharm Co Ltd and is included in one NDA. It is available from one supplier. There are thirty-one patents protecting this drug. Additional details are available on the ABILIFY MYCITE KIT profile page.

The generic ingredient in ABILIFY MYCITE KIT is aripiprazole. There are forty-nine drug master file entries for this compound. Forty-two suppliers are listed for this compound. Additional details are available on the aripiprazole profile page.
Summary for 207202
Tradename:ABILIFY MYCITE KIT
Applicant:Otsuka Pharm Co Ltd
Ingredient:aripiprazole
Patents:31
Formulation / Manufacturing:see details
Pharmacology for NDA: 207202
Medical Subject Heading (MeSH) Categories for 207202
Suppliers and Packaging for NDA: 207202
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202 NDA Otsuka America Pharmaceutical, Inc. 59148-029 59148-029-85 1 BOTTLE in 1 KIT (59148-029-85) > 30 TABLET in 1 BOTTLE (59148-029-13)
ABILIFY MYCITE KIT aripiprazole TABLET;ORAL 207202 NDA Otsuka America Pharmaceutical, Inc. 59148-029 59148-029-90 1 BOTTLE in 1 CARTON (59148-029-90) > 30 TABLET in 1 BOTTLE (59148-029-07)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength2MG
Approval Date:Nov 13, 2017TE:RLD:Yes
Regulatory Exclusivity Expiration:Jul 27, 2020
Regulatory Exclusivity Use:NEW INDICATION OF MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER IN ADULTS
Patent:  Start TrialPatent Expiration:May 12, 2029Product Flag?YSubstance Flag?Delist Request?
Patent:  Start TrialPatent Expiration:Jan 28, 2022Product Flag?Substance Flag?Delist Request?
Patented Use:ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Mallinckrodt
Harvard Business School
Express Scripts
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.